

98. (New) The process of claim 71 wherein the T cells are from the recipient and the xenoantigen is from the donor.

99. (New) The process of claim 71 wherein said T cells are present in a transplant.

<sup>100</sup>  
~~101.~~ (New) The process of claim 71 wherein said MSCs are administered to a transplant recipient suffering from graft-versus-host disease.

<sup>101</sup>  
~~102.~~ (New) The process of claim 71 wherein prior to said administration said mesenchymal stem cells (MSCs) have been expanded in culture.

<sup>102</sup>  
~~103.~~ (New) The process of claim 71 wherein said effector cells are T cells previously activated and said immune response is the reactivation of said T cells.

<sup>103</sup>  
~~104.~~ (New) The process of claim 71 wherein the transplant is skin.

<sup>104</sup>  
~~105.~~ (New) The process of claim 71 wherein the mesenchymal stem cells are administered to the transplant recipient to treat rejection of the transplant by the recipient.

<sup>105</sup>  
~~106.~~ (New) The process of claim 71 wherein the mesenchymal stem cells are human mesenchymal stem cells.

<sup>106</sup>  
~~107.~~ (New) The process of claim 71 further comprising administering to the recipient immunosuppressive agents.

<sup>107</sup>  
~~108.~~ (New) The process of claim 71 wherein the transplant is a solid organ.

<sup>108</sup>  
~~109.~~ (New) The process of claim 108 wherein the solid organ is selected from heart, pancreas, kidney, lung or liver.

<sup>109</sup>~~110~~. (New) The process of claim 71 wherein said mesenchymal stem cells are administered prior to said transplant.

<sup>110</sup>~~111~~. (New) The process of claim 71 wherein said mesenchymal stem cells are administered concurrently with said transplant.

<sup>111</sup>~~112~~. (New) The process of claim 71 wherein said mesenchymal stem cells are administered as part of the transplant.

<sup>112</sup>~~113~~. (New) The process of claim 71 wherein the mesenchymal stem cells are administered subsequent to transplant.

<sup>113</sup>~~114~~. (New) The process of claim 71 wherein said mesenchymal stem cells are administered intravenously to the recipient.

<sup>114</sup>~~115~~. (New) The process of claim 71 wherein said effector cells are cells of a recipient of said donor transplant.

<sup>115</sup>~~116~~. (New) A process for treating a transplant recipient to reduce in said recipient an immune response of effector cells against a xenoantigen to the effector cells, comprising:

transplanting to a transplant recipient a transplant treated with mesenchymal stem cells in an amount effective to reduce an immune response of effector cells against a xenoantigen to the effector cells, whereby in the transplant recipient the effector cells have a reduced immune response against the xenoantigen.

<sup>116</sup>~~117~~. (New) The process of claim <sup>115</sup>~~116~~ wherein said effector cells are T cells.